LearnGlossaryMarketStocksSuperinvestorsSign in

AUTL

Autolus Therapeutics plc

Healthcare · $496M market cap

Verdict

We can't put a fair value on AUTL right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-27.7% a year✗
Sales growth130.2% a year✓
Free cash flow growth—?
Return on invested capital-46.1%✗

Follow AUTL

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 1, 2026: no open-market purchases, 1 sale worth $16K and 2 other filings (stock awards, tax withholding and similar). Why purchases matter

Sales

Piccina Cintia

U.S. CCO & Country Gen Manager · 2026-09-02

Sold

$16K

Other filings

Piccina Cintia

U.S. CCO & Country Gen Manager · 2026-09-01

Option exercise

20,000 shares

Piccina Cintia

U.S. CCO & Country Gen Manager · 2026-09-01

Option exercise

$47K

About Autolus Therapeutics plc

Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works